First third-generation CAR T cell application targeting CD19 for the treatment of systemic IgM AL amyloidosis with underlying marginal zone lymphoma

First third-generation CAR T cell application targeting CD19 for the treatment of systemic IgM AL amyloidosis with underlying marginal zone lymphoma

Abstract Light chain amyloidosis (AL) is a rare disease caused by the generalized deposition of misfolded free light chains. Patients with immunoglobulin M gammopathy (IgM) and indolent B-cell lymphoma such as marginal zone lymphoma (MZL) may in some instances develop AL amyloidosis. So far, CAR T c...

Full description

Bibliographic Details
Main Authors: Felix Korell, Stefan Schönland, Anita Schmitt, Madelaine Jansen, Kiavasch Farid, Carsten Müller-Tidow, Peter Dreger, Michael Schmitt, Ute Hegenbart
Format: Article
Language:English
Published: BMC 2023-10-01
Series:Biomarker Research
Subjects:
CAR T cell therapy
Amyloidosis
Free light chains
IgM
Marginal zone lymphoma
Online Access:https://doi.org/10.1186/s40364-023-00532-2

Internet

https://doi.org/10.1186/s40364-023-00532-2

Similar Items